Ra Pharma to host conference call June 27 to discuss mid-stage results for PNH candidate RA101495

|About: Ra Pharmaceuticals (RARX)|By:, SA News Editor

Ra Pharmaceuticals (NASDAQ:RARX) will host a conference call on Tuesday, June 27, at 8:00 am ET to discuss preliminary data from its Phase 2 clinical trial assessing lead candidate RA101495 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Patient dosing started in late April.

RA101495 is a subcutaneously administered inhibitor of complement component 5 (C5).

Previously: Mid-stage study underway assessing Ra Pharma's RA101495 for PNH (April 26)

Subscribe for full text news in your inbox